Back to top

cell-therapy: Archive

Zacks Equity Research

IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi

Iovance shares plunge after Q2 miss and voluntary withdrawal of Amtagvi's EU filing, despite strong U.S. sales growth for the therapy.

CRMDNegative Net Change IOVANegative Net Change GMABNegative Net Change IMCRPositive Net Change